Literature DB >> 10798077

Pediatric transfusion therapy: practical considerations.

R Kulkarni1, R Gera.   

Abstract

Over the past decade, safety of blood has increased tremendously because of better donor screening as well as testing of the units for transmissible diseases. Component therapy has allowed more effective and economic use of blood. Whole blood is rarely used; instead, packed red cells, platelets, and fresh frozen plasma (FFP) are the most common components used. These products are further refined using irradiation and microaggregate filters and in the case of FFP, viral inactivation. Irradiation prevents transfusion-associated graft versus host disease, whereas microaggregate filters remove leukocytes, decreasing the rates of alloimmunization, febrile nonhemolytic (FNH) reactions, and cytomegalovirus (CMV) transmission. Autologous donation in older children probably provides the safest blood as far as transmissible diseases are concerned. More families request a directed donation and solicit physician help in deciding as well as making arrangements for autologous and/or directed donations. Transfusions of blood and blood components in children are often challenging and require a knowledge of physiologic changes in hemoglobin and blood volumes during different ages. The unique needs of neonates, immunocompromised patients, and patients with congenital hemolytic anemia (sickle cell, thalassemia) mandate that the pediatrician have an appropriate knowledge of transfusion volumes and choice of blood product as well as indications for transfusion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10798077     DOI: 10.1007/bf02845512

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  18 in total

Review 1.  Massive blood transfusion.

Authors:  M D Donaldson; M J Seaman; G R Park
Journal:  Br J Anaesth       Date:  1992-12       Impact factor: 9.166

2.  The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.

Authors:  L A GAYDOS; E J FREIREICH; N MANTEL
Journal:  N Engl J Med       Date:  1962-05-03       Impact factor: 91.245

3.  Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy.

Authors: 
Journal:  Anesthesiology       Date:  1996-03       Impact factor: 7.892

Review 4.  Management of pediatric transfusions.

Authors:  N L Luban
Journal:  Vox Sang       Date:  1994       Impact factor: 2.144

5.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

Authors:  P Rebulla; G Finazzi; F Marangoni; G Avvisati; L Gugliotta; G Tognoni; T Barbui; F Mandelli; G Sirchia
Journal:  N Engl J Med       Date:  1997-12-25       Impact factor: 91.245

6.  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.

Authors: 
Journal:  N Engl J Med       Date:  1997-12-25       Impact factor: 91.245

7.  Autologous blood donation for elective surgery in children weighing 8-25 kg.

Authors:  M N Mayer; M de Montalembert; F Audat; M C Brusset; B Houfani; J Merckx; G Barrier; C Gazengel
Journal:  Vox Sang       Date:  1996       Impact factor: 2.144

8.  Transfusion therapy for severe anemia.

Authors:  S Jayabose; O Tugal; R Ruddy; D Wuest; D Ciavarella
Journal:  Am J Pediatr Hematol Oncol       Date:  1993-08

9.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.

Authors:  G B Schreiber; M P Busch; S H Kleinman; J J Korelitz
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

10.  Predeposited autologous blood transfusion for surgery in infants and children.

Authors:  H Kemmotsu; K Joe; H Nakamura; M Yamashita
Journal:  J Pediatr Surg       Date:  1995-05       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.